Suriet 1: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 2: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 3: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 4: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 5: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 6: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 7: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 8: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 9: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 10: Plenary session- Disclosures relating to sustainable investments and sustainability risks
Suriet 11: Plenary session- European Maritime Single Window environment
Suriet 12: Plenary session- European Maritime Single Window environment
Suriet 13: Plenary session- European Maritime Single Window environment
Suriet 14: Plenary session- European Maritime Single Window environment
Suriet 15: Plenary session- European Maritime Single Window environment
Suriet 16: Plenary session- European Maritime Single Window environment
Suriet 17: Plenary session- European Maritime Single Window environment
Suriet 18: Plenary session- European Maritime Single Window environment
Suriet 19: Plenary session- European Maritime Single Window environment
Suriet 20: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 21: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 22: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 23: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 24: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 25: Plenary sessionA comprehensive European Union framework on endocrine disruptors
Suriet 26: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 27: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 28: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 29: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 30: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 31: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 32: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 33: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 34: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 35: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 36: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 37: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 38: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 39: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 40: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 41: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 42: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 43: Plenary sessionChina, notably the situation of religious and ethnic minorities
Suriet 44: Plenary sessionA comprehensive European Union framework on endocrine disruptors